ATE447399T1 - Impfstoffvorläufer, impfstoffe zur behandlung von krebs - Google Patents

Impfstoffvorläufer, impfstoffe zur behandlung von krebs

Info

Publication number
ATE447399T1
ATE447399T1 AT98901030T AT98901030T ATE447399T1 AT E447399 T1 ATE447399 T1 AT E447399T1 AT 98901030 T AT98901030 T AT 98901030T AT 98901030 T AT98901030 T AT 98901030T AT E447399 T1 ATE447399 T1 AT E447399T1
Authority
AT
Austria
Prior art keywords
antibodies
antitoxins
vaccines
agents
molecular
Prior art date
Application number
AT98901030T
Other languages
English (en)
Inventor
Shozo Koyama
Satoshi Tanaka
Original Assignee
Shozo Koyama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shozo Koyama filed Critical Shozo Koyama
Application granted granted Critical
Publication of ATE447399T1 publication Critical patent/ATE447399T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98901030T 1997-01-29 1998-01-28 Impfstoffvorläufer, impfstoffe zur behandlung von krebs ATE447399T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP02829597A JP3813682B2 (ja) 1997-01-29 1997-01-29 ワクチン前駆体およびワクチン
PCT/JP1998/000351 WO1998032431A1 (fr) 1997-01-29 1998-01-28 Inducteurs antigenes, precurseurs de vaccin, vaccins, anticorps, anticorps neutralisants, antitoxines, anticorps idiotypiques, et anticorps anti-idiotypiques induits par lesdits anticorps idiotypiques

Publications (1)

Publication Number Publication Date
ATE447399T1 true ATE447399T1 (de) 2009-11-15

Family

ID=12244637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98901030T ATE447399T1 (de) 1997-01-29 1998-01-28 Impfstoffvorläufer, impfstoffe zur behandlung von krebs

Country Status (7)

Country Link
EP (1) EP1004299B1 (de)
JP (1) JP3813682B2 (de)
AT (1) ATE447399T1 (de)
AU (1) AU5678698A (de)
CA (1) CA2279196C (de)
DE (1) DE69841271D1 (de)
WO (1) WO1998032431A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8409564B2 (en) 1999-10-05 2013-04-02 Universite De Montreal Rhodamine derivatives for photodynamic diagnosis and treatment
AU2004294243B2 (en) * 2003-12-05 2011-02-17 Hopital Maisonneuve-Rosemont Immunologic compounds for prevention, protection, prophylaxis or treatment of immunological disorders, infections and cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100418202B1 (ko) * 1994-09-09 2004-07-05 쇼죠 고야마 분자발현기능의억제방법
DK1666591T3 (da) * 1995-06-29 2011-05-23 Immunex Corp Cytokin der inducerer apoptose
JPH09221421A (ja) * 1996-02-13 1997-08-26 Kyowa Hakko Kogyo Co Ltd 抗アポトーシス剤

Also Published As

Publication number Publication date
CA2279196A1 (en) 1998-07-30
AU5678698A (en) 1998-08-18
EP1004299A4 (de) 2004-01-02
JPH10212229A (ja) 1998-08-11
CA2279196C (en) 2011-11-01
JP3813682B2 (ja) 2006-08-23
WO1998032431A1 (fr) 1998-07-30
EP1004299B1 (de) 2009-11-04
DE69841271D1 (de) 2009-12-17
EP1004299A1 (de) 2000-05-31

Similar Documents

Publication Publication Date Title
ES8203226A1 (es) Procedimiento de preparar complejos vacunantes por reaccion de arn ribonosales y de antigenos especificos.
DE69233435D1 (de) Vorläufer von für tumorabstossung verantwortlichen antigenen, die antigene und deren verwendungen
ATE369428T1 (de) Behandlung von gebärmutterhalskrebs
DE69941165D1 (de) CD40 bindende Moleküle und CTL Peptide zur Behandlung von Tumoren
EP1103564A4 (de) Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
ATE535254T1 (de) Behandlung von krebs mit dem anti-erbb2- antikörper rhumab 2c4
DK0845032T3 (da) Isolerede nucleinsyremolekyler, peptider, der danner komplekser med MHC-molekyler HLA-A2, samt anvendelser
EP2364727A3 (de) Molekulares Antigen-Array
MXPA03007316A (es) Metodo para la identificacion de epitopes de celulas t y el uso para la preparacion de moleculas con inmunogenicidad reducida.
FI956019A0 (fi) Eristettyjä peptidejä, jotka muodostavat komplekseja MHC-molekyyli HLA-C-klooni-10:n kanssa, ja niiden käyttö
DE69333433D1 (de) Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
ATE391726T1 (de) Modifiziertes gp100 und dessen verwendung
DE3789082D1 (de) Expression eines tumorspezifischen Antigens eines rekombinanten Virusvektors sowie dessen Anwendung zur versorgenden oder heilenden Behandlung des entsprechenden Tumors.
DE59309239D1 (de) Verfahren zur Isolierung und Kultivierung von transformierten Zellen sowie Verwendung dieser Zellen zur Herstellung individuumsspezifischer Antikörper
NO923659L (no) Gp75 som en tumorvaksine for melanom
ATE447399T1 (de) Impfstoffvorläufer, impfstoffe zur behandlung von krebs
ATE312845T1 (de) Verfahren zur herstellung von katalytischen antikörpern
NZ302821A (en) isolated truncated nucleic acid molecules which code for GAGE tumour rejection antigen precursors
ATE369895T1 (de) Modifizierte cea nucleinsäure und expressionsvektoren
EA200300638A1 (ru) Вакцинная композиция, содержащая трансформирующий фактор роста альфа
EP0328578A4 (de) Von mca 16-88 erkanntes antigen.
ATE396742T1 (de) Komplexe mit adjuvanter wirkung
WO2001030989A3 (en) Method for creating divergent populations of nucleic acid molecules and proteins
Chou et al. Primary processes in the photolysis of water vapor at 174 nm
Roh Creation and redemption in Priestly theology.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties